Proshares Trust ZBIO
ZBIO
$28.30 +0.36 (+1.29%)
At close: Oct 2, 2026 · 4:00 PM EDT

Zenas BioPharma (ZBIO) Gains from Sales and Divestitures (2025)

Updated

Zenas BioPharma (ZBIO) reported Gains from Sales and Divestitures of -$107,000 for FY2025.

Analysis

Zenas BioPharma (ZBIO) Gains from Sales and Divestitures (2025) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Zenas BioPharma 1.79 Bn 1.79 Bn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2025 -107,000.00
API Access

Zenas BioPharma Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=ZBIO&period=max&api_key=YOUR_API_KEY